{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:29Z","timestamp":1775728889144,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03490-x","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:25:34Z","timestamp":1769498734000},"page":"1486-1499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Value Contribution of Vyvgart\u00ae (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmina","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Toja-Camba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda R.","family":"Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Mart\u00edn Mach\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"1","key":"3490_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"key":"3490_CR2","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de efgartigimod alfa (Vyvgart\u00ae) en Miastenia Gravis Generalizada. [cited 2024 Jun 10]. https:\/\/svadcf.es\/documentos\/images_ipt\/pdf\/IPT-173-Efgartigimod-alfa-vyvgar-miastenia.pdf."},{"issue":"6","key":"3490_CR3","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC, Mart\u00ednez E, Segovia S, Arribas-Velasco M, et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol. 2021;28(6):2083\u201391.","journal-title":"Eur J Neurol"},{"issue":"11","key":"3490_CR4","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171\u201380.","journal-title":"Neurology"},{"issue":"9","key":"3490_CR5","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/acn3.52122","volume":"11","author":"E Cort\u00e9s-Vicente","year":"2024","unstructured":"Cort\u00e9s-Vicente E, Borsi AJ, Gary C, Noel WGJ, Lee JMS, Karmous W, et al. The impact of diagnosis delay on European patients with generalised myasthenia gravis. Ann Clin Transl Neurol. 2024;11(9):2254\u201367.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"3490_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, et al. Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol. 2022;9(2):122\u201331.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"3490_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.nrl.2020.09.004","volume":"38","author":"I D\u00edaz-Maroto","year":"2023","unstructured":"D\u00edaz-Maroto I, Garc\u00eda-Garc\u00eda J, S\u00e1nchez-Ayaso PA, Alcahut-Rodr\u00edguez C, Gonz\u00e1lez-Villar E, Pardal-Fern\u00e1ndez JM, et al. Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series. Neurologia. 2023;38(4):229\u201335.","journal-title":"Neurologia"},{"issue":"1","key":"3490_CR8","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","volume":"10","author":"L D\u00edez-Porras","year":"2020","unstructured":"D\u00edez-Porras L, Homedes C, Alberti MA, V\u00e9lez-Santamar\u00eda V, Casasnovas C. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020;10(1):13497.","journal-title":"Sci Rep"},{"issue":"5\u20136","key":"3490_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000502818","volume":"81","author":"G Karelis","year":"2019","unstructured":"Karelis G, Balasa R, De Bleecker JL, Stuchevskaya T, Villa A, Van Damme P, et al. A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate\/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81(5\u20136):223\u201330.","journal-title":"Eur Neurol"},{"issue":"1","key":"3490_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","volume":"18","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, DeCourcy J, Golden K, Gibson G, Taylor C, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169.","journal-title":"Orphanet J Rare Dis"},{"issue":"31","key":"3490_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16511","volume":"1","author":"F Piehl","year":"2024","unstructured":"Piehl F, Vissing J, Meht\u00e4l\u00e4 J, Berggren F, Lindberg-Schager I, Pitsi D, et al. Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: a population-based registry study. Eur J Neurol. 2024;1(31):e16511.","journal-title":"Eur J Neurol"},{"issue":"2","key":"3490_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"issue":"7","key":"3490_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, M\u00e1rquez-Infante C, Pardo J, Coll-Cant\u00ed J, et al. Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol. 2015;22(7):1056\u201361.","journal-title":"Eur J Neurol"},{"key":"3490_CR14","doi-asserted-by":"publisher","first-page":"e16180","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31:e16180.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3490_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis\u2014results from population based cohorts. Health Qual Life Outcomes. 2015;13(1):115.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"3490_CR16","volume":"12","author":"C Law","year":"2020","unstructured":"Law C, Flaherty CV, Bandyopadhyay S. A review of psychiatric comorbidity in myasthenia gravis. Cureus. 2020;12(7):e9184.","journal-title":"Cureus"},{"issue":"4","key":"3490_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Ciusani E, Bonanno S, et al. Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol. 2024;31(4):e16189.","journal-title":"Eur J Neurol"},{"key":"3490_CR18","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.","journal-title":"Front Neurol"},{"issue":"2","key":"3490_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.nrl.2020.06.011","volume":"38","author":"DA Garc\u00eda Est\u00e9vez","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, L\u00f3pez D\u00edaz LM, Pardo Parrado M, P\u00e9rez Lorenzo G, Sabbagh Casado NA, Ozaita Arteche G, et al. Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain). Neurologia. 2023;38(2):75\u201381.","journal-title":"Neurologia"},{"key":"3490_CR20","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Investig. 2006;116:2843\u201354.","journal-title":"J Clin Investig"},{"key":"3490_CR21","unstructured":"Cort\u00e9s E, Hern\u00e1ndez R, Mart\u00ednez E, Pardo J, Rodr\u00edguez de Rivera FJ. Protocolo de tratamiento para la Miastenia Gravis generalizada con anticuerpos antirreceptor de acetilcolina (MGg AChR+). Documento de consenso. 2023."},{"issue":"1","key":"3490_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","volume":"32","author":"JM Aragon\u00e8s","year":"2017","unstructured":"Aragon\u00e8s JM, Altimiras J, Roura P, Alonso F, Bufill E, Munmany A, et al. Prevalence of myasthenia gravis in the Catalan county of Osona. Neurologia. 2017;32(1):1\u20135.","journal-title":"Neurologia"},{"issue":"4","key":"3490_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nrleng.2023.04.001","volume":"38","author":"J Garcia-Garcia","year":"2023","unstructured":"Garcia-Garcia J, D\u00edaz-Maroto I, Mart\u00ednez-Mart\u00edn A, Pardal-Fern\u00e1ndez JM, Segura T. A series of patients with refractory myasthenia gravis. Neurolog\u00eda (Engl Ed). 2023;38(4):256\u201361.","journal-title":"Neurolog\u00eda (Engl Ed)"},{"key":"3490_CR24","doi-asserted-by":"crossref","unstructured":"Howard Jr JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20. www.thelancet.com\/neurology.","DOI":"10.1212\/WNL.96.15_supplement.4520"},{"key":"3490_CR25","unstructured":"European Medicines Agency (EMA). Summary of product characteristics of vyvgart. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf."},{"issue":"1","key":"3490_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making\u2014an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health. 2016;19(1):1\u201313.","journal-title":"Value in Health"},{"issue":"3","key":"3490_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40273-014-0235-x","volume":"33","author":"M Paulden","year":"2015","unstructured":"Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255\u201369. https:\/\/doi.org\/10.1007\/s40273-014-0235-x.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3490_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","volume":"12","author":"L Annemans","year":"2017","unstructured":"Annemans L, Aym\u00e9 S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50. https:\/\/doi.org\/10.1186\/s13023-017-0601-9.","journal-title":"Orphanet J Rare Dis"},{"key":"3490_CR29","doi-asserted-by":"crossref","unstructured":"Zozaya Gonz\u00e1lez N, Oliva Moreno J, Hidalgo Vega \u00c1, Garc\u00eda Ruiz A, Garc\u00eda-Agua Soler N, Puig-Junoy J, et al. El An\u00e1lisis de Decisi\u00f3n Multi-Criterio en el \u00e1mbito sanitario: utilidad y limitaciones en la toma de decisiones. Fundaci\u00f3n Weber; 2018. http:\/\/weber.org.es\/wp-content\/uploads\/2019\/02\/Libro-ADMC-17-x-24-ESPA\u00d1OL-DIGITAL.pdf.","DOI":"10.37666\/L6-2018"},{"issue":"3","key":"3490_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40273-015-0340-5","volume":"34","author":"M Wagner","year":"2016","unstructured":"Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34(3):285\u2013301. https:\/\/doi.org\/10.1007\/s40273-015-0340-5.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"3490_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/0272989X11416870","volume":"32","author":"MM Goetghebeur","year":"2012","unstructured":"Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32(2):376\u201388.","journal-title":"Med Decis Mak"},{"issue":"1","key":"3490_CR32","doi-asserted-by":"publisher","first-page":"001","DOI":"10.24875\/SANGRE.M23000006","volume":"42","author":"J Villarubia","year":"2023","unstructured":"Villarubia J, Reyes-Abad M, Gonz\u00e1lez-Meneses A, Gras-Colomer E, Poveda JL, Trillo JL, et al. Contribuci\u00f3n de valor de olipudase alfa en el tratamiento de las manifestaciones no relacionadas con el SNC del d\u00e9ficit de esfingomielinasa \u00e1cida mediante an\u00e1lisis de decisi\u00f3n multicriterio. Revista Sangre. 2023;42(1):001\u201311.","journal-title":"Revista Sangre"},{"issue":"1","key":"3490_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-024-03324-5","volume":"19","author":"X Badia","year":"2024","unstructured":"Badia X, Calleja M\u00c1, Escudero-Vilaplana V, P\u00e9rez-Mart\u00ednez A, Pi\u00f1ana JL, Poveda JL, et al. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Orphanet J Rare Dis. 2024;19(1):1\u201313. https:\/\/doi.org\/10.1186\/s13023-024-03324-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3490_CR34","doi-asserted-by":"publisher","first-page":"108711","DOI":"10.1016\/j.yebeh.2022.108711","volume":"132","author":"A Gil-Nagel","year":"2022","unstructured":"Gil-Nagel A, Falip M, S\u00e1nchez-Carpintero R, Abad-Sazatornil MR, Poveda JL, Aibar J\u00c1, et al. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through multi-criteria decision analysis. Epilepsy Behav. 2022;132:108711.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"3490_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0966-4","volume":"13","author":"A Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez A, Ais A, Beaudet A, Gil A. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). Orphanet J Rare Dis. 2018;13(1):1\u201311. https:\/\/doi.org\/10.1186\/s13023-018-0966-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3490_CR36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/hae.15096","volume":"30","author":"DA Garc\u00eda-Diego","year":"2024","unstructured":"Garc\u00eda-Diego DA, Badia X, Ben\u00edtez-Hidalgo O, Jim\u00e9nez V, Ju\u00e1rez JC, N\u00fa\u00f1ez R, et al. Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis. Haemophilia. 2024;30:1281\u20137.","journal-title":"Haemophilia"},{"issue":"1","key":"3490_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(1):74. https:\/\/doi.org\/10.1186\/1750-1172-7-74.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3490_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1472-6963-8-270","volume":"8","author":"MM Goetghebeur","year":"2008","unstructured":"Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and value: impact on DEcisionMaking\u2014the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8(1):270. https:\/\/doi.org\/10.1186\/1472-6963-8-270.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3490_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S0266462317000149","volume":"33","author":"A Gilabert-Perramon","year":"2017","unstructured":"Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peir\u00f3 R, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33(1):111\u201320.","journal-title":"Int J Technol Assess Health Care"},{"key":"3490_CR40","unstructured":"Orphar-SEFH. Manual para el desarrollo de un informe de evaluaci\u00f3n de medicamentos hu\u00e9rfanos por parte del grupo ORPHAR-SEFH usando metodolog\u00eda de An\u00e1lisis de Decisi\u00f3n Multicriterio. 2020. https:\/\/gruposdetrabajo.sefh.es\/orpharsefh\/images\/stories\/documentos\/Manual_MCDA_Orphar_SEFH_060520.pdf."},{"issue":"7\u20138","key":"3490_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/21678707.2019.1652163","volume":"7","author":"X Badia","year":"2019","unstructured":"Badia X, Chugani D, Abad MR, Arias P, Guill\u00e9n-Navarro E, Jarque I, et al. Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain. Expert Opin Orphan Drugs. 2019;7(7\u20138):363\u201372. https:\/\/doi.org\/10.1080\/21678707.2019.1652163.","journal-title":"Expert Opin Orphan Drugs"},{"key":"3490_CR42","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jval.2018.09.052","volume":"21","author":"X Badia","year":"2018","unstructured":"Badia X, Calleja M, Mirco A, Poveda J, Gil A. Ht6 - Do Spain and Portugal evaluators and decision makers give the same importance to evaluation criteria of innovative medicines? Value Health. 2018;21:S9. https:\/\/doi.org\/10.1016\/j.jval.2018.09.052.","journal-title":"Value Health"},{"key":"3490_CR43","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.jval.2018.09.1063","volume":"21","author":"X Badia","year":"2018","unstructured":"Badia X, Gil A, Shepherd J. PHP169\u2014MCDA EVIDEM reference value framework for drug evaluation and decision making in Spain. Value Health. 2018;21:S179.","journal-title":"Value Health."},{"key":"3490_CR44","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de rozanolixizumab ( Rystiggo\u00ae) como complemento de la terapia est\u00e1ndar para el tratamiento de la miastenia gravis generalizada en pacientes adultos con anticuerpos positivos frente a AChR o MuSK. 2024;1\u201323."},{"key":"3490_CR45","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de zilucopl\u00e1n ( Zilbrysq\u00ae) como complemento a la terapia est\u00e1ndar para el tratamiento de pacientes adultos con miastenia gravis generalizada con anticuerpos positivos frente a receptores de acetilcolina. 2024;(1):1\u201322."},{"key":"3490_CR46","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de ravulizumab (Ultomiris\u00ae) en Miastenia Gravis Generalizada. 2023;1\u201327. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2023\/IPT-178-Ultomiris-ravulizumab-miastenia-gravis.pdf."},{"issue":"12","key":"3490_CR47","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.1016\/j.jval.2022.09.1588","volume":"25","author":"M Abad","year":"2022","unstructured":"Abad M, Gonz\u00e1lez-Meneses A, Gras E, Poveda J, Trillo J, de Vicente D, et al. HTA130 value contribution of olipudase alfa therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) by multi-criteria decision analysis (MCDA). Value Health. 2022;25(12):S321\u20132.","journal-title":"Value Health."},{"issue":"5","key":"3490_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/jcm11051353","volume":"11","author":"M Gasol","year":"2022","unstructured":"Gasol M, Paco N, Guarga L, Bosch J\u00c0, Pontes C, Obach M. early access to medicines: use of multicriteria decision analysis (MCDA) as a decision tool in Catalonia (Spain). J Clin Med. 2022;11(5):1353.","journal-title":"J Clin Med"},{"issue":"5","key":"3490_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1017\/S0266462318000569","volume":"34","author":"\u00daB Rold\u00e1n","year":"2018","unstructured":"Rold\u00e1n \u00daB, Badia X, Marcos-Rodr\u00edguez JA, De La Cruz-Merino L, G\u00f3mez-Gonz\u00e1lez J, Melc\u00f3n-De Dios A, et al. Multi-criteria decision analysis as a decision-support tool for drug evaluation: a pilot study in a pharmacy and therapeutics committee setting. Int J Technol Assess Health Care. 2018;34(5):519\u201326.","journal-title":"Int J Technol Assess Health Care"},{"key":"3490_CR50","unstructured":"Plan_Estratgico_OrPhar-SEFH_2024-2027."},{"key":"3490_CR51","first-page":"122","volume":"1","author":"V Villanueva","year":"2021","unstructured":"Villanueva V, Carre\u00f1o M, Gil-Nagel A, Serrano-Castro PJ, Serratosa JM, Toledo M, et al. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through multi-criteria decision analysis (MCDA). Epilepsy Behav. 2021;1:122.","journal-title":"Epilepsy Behav"},{"key":"3490_CR52","doi-asserted-by":"crossref","unstructured":"Taxonera C, Sala F, Mart\u00edn I, Nazco J, Mar\u00edn L, Nos P, et al. Determinaci\u00f3n de la contribuci\u00f3n de valor de filgotinib para el tratamiento de la colitis ulcerosa de moderada a grave mediante el an\u00e1lisis de decisi\u00f3n multicriterio (MCDA). Econom\u00eda de la Salud. 2023;18.","DOI":"10.61679\/1803031044"},{"issue":"1","key":"3490_CR53","first-page":"1","volume":"6","author":"MT \u00c1lvarez-Rom\u00e1n","year":"2019","unstructured":"\u00c1lvarez-Rom\u00e1n MT, Cuervo-Arango I, P\u00e9rez-Santamarina R, Poveda JL, Romero JA, Santamar\u00eda A, et al. Determining the value contribution of emicizumab (Hemlibra\u00ae) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Glob Region Health Technol Assess. 2019;6(1):1\u20138.","journal-title":"Glob Region Health Technol Assess"},{"issue":"1","key":"3490_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40258-022-00770-9","volume":"21","author":"C Domingo","year":"2023","unstructured":"Domingo C, Fernandez M, Garin N, Milara J, Moran I, Muerza I, et al. Determining what represents value in the treatment of refractory or unexplained chronic cough from the perspective of key stakeholders in spain using multi-criteria decision analysis. Appl Health Econ Health Policy. 2023;21(1):119\u201330.","journal-title":"Appl Health Econ Health Policy"}],"updated-by":[{"DOI":"10.1007\/s12325-026-03532-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03490-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:51Z","timestamp":1775726031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3490"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03490-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03532-4","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03532-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mar\u00eda R. Abad: I declare that I have received honoraria for the development of this project from argenx and speakers\u2019 fees from UCB Pharma, Johnson & Johnson, Vertex, Organon, Biogen, CINFA, Astra Zeneca, GSK, and Sanofi Aventis. Elena Cort\u00e9s-Vicente: I declare that I have received honoraria for speaking engagements and consultancy activities from argenx, UCB, Alexion, and Janssen. Francisco J. Toja-Camba: I declare that I have received honoraria for the development of this project from argenx. Carmina D\u00edaz: I declare that I have received honoraria for the development of this project from argenx. Included received speakers fees from ALEXION and UCB. Eva Mart\u00ednez: I declare that I have received honoraria for the development of this project from argenx. Jos\u00e9 M. Serra: I declare that I have received honoraria for the development of this project from argenx. Jose L. Trillo: I declare that I have received honoraria for the development of this project from argenx. Antonio Guerrero: I declare that I have received honoraria for the development of this project from argenx and received speaker\u2019s fees from ALEXION and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors declare that no experiments on humans or animals have been carried out for this research. The authors declare that no patient data appear in this article. Full consent to participate in the study and to publish the findings was obtained from all contributors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}